vevorisertib

Vevorisertib (ARQ 751) is an orally bioavailable, potent, and selective small molecule inhibitor of the serine/threonine kinase AKT (also known as protein kinase B), targeting all three isoforms: AKT1, AKT2, and AKT3. It acts by blocking phosphorylation of AKT, thereby inhibiting the PI3K/AKT/mTOR signaling pathway that is frequently activated in various cancers. Vevorisertib has been investigated primarily for the treatment of advanced solid tumors and hepatocellular carcinoma (HCC), both as a monotherapy and in combination with other agents such as sorafenib or paclitaxel. The drug was originally developed by ArQule and later by Merck & Co. Clinical development reached phase 1 trials but was terminated due to business decisions[1][4][5][6][7].

Brand names

vevorisertib

Other names

1416775-46-6V6SX910Y31V-6SX910Y31V 6SX910Y31UNII-V6SX910Y31UNII-V-6SX910Y31UNII-V 6SX910Y31